Comparative Pharmacology
Head-to-head clinical analysis: BRIVARACETAM versus ZONISAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVARACETAM versus ZONISAMIDE.
BRIVARACETAM vs ZONISAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
Anticonvulsant; blocks voltage-gated sodium channels and T-type calcium channels, reducing neuronal excitability and seizure propagation. Also weakly inhibits carbonic anhydrase.
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
Oral, initial 100 mg daily, may increase by 100 mg every 2 weeks; maintenance 200-400 mg daily in 1-2 divided doses; maximum 600 mg daily.
None Documented
None Documented
Clinical Note
moderateZonisamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Zonisamide."
Clinical Note
moderateBrivaracetam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brivaracetam."
Clinical Note
moderateZonisamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Zonisamide."
Clinical Note
moderateBrivaracetam + Erythromycin
Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment.
Terminal half-life approximately 60-70 hours (range 50-80 hours) in adults; at steady state, half-life may be slightly longer. Clinical context: requires 2-3 weeks to achieve steady state.
Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%.
Renal: approximately 30% unchanged; remainder as glucuronide conjugate and reduced metabolite. Biliary/fecal: minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Erythromycin can be decreased when combined with Brivaracetam."